198 results
Page 5 of 10
8-K
EX-2.2
4r2jfn5 8k01kn
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.3
s6ak cwnq3f5
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-99.1
cmqtrp aaqa4h
24 Mar 22
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-10.1
413007w1
4 Mar 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
lzo5s8v
19 Jan 22
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739
7:42am
8-K
EX-99.1
tv24d
15 Nov 21
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
7:42am
8-K
EX-99.1
wdqfq
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.2
00525tt4ap0gj
10 Nov 21
Regulation FD Disclosure
7:12am
8-K
EX-99.1
iizrp6sunexmqbwj8
16 Aug 21
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
7:21am
8-K
EX-99.1
mcesoxyrct1nkm1 mxq
12 Aug 21
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
4:21pm
8-K
EX-99.1
0dnervn
16 Jun 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
9gnnbd92570 nz9i9v7
17 May 21
Regulation FD Disclosure
5:03pm